Breaking News Instant updates and real-time market news.

2023-01-30 09:05:02 $ECON Economic Data / + 09:05 01/30/23 01/30 09:05 01/30/23 09:05	The FOMC meets for the first time in 2023 on Tuesday, Wednesday The FOMC meets for the first time in 2023 on Tuesday, Wednesday. The policy decision will be announced on Wednesday at 14:00 ET. A stepped down 25 bp hike to a 4.625% rate is widely expected after downshifting to 50 bps in December following four straight 75 bp boosts. Comments from Governor Waller, one of the most hawkish on the Committee, who added his support for a further tapering to 25 bps largely sealed the deal. But, many believe a 50 bps is warranted. Recent data reflect still tight claims numbers and elevated inflation. Also policymakers' desire to achieve the terminal rate as quickly as possible argue for a 50 bps increase. Additionally, the financial markets have continued to ease, something Powell was concerned about and which showed up in the December minutes: "participants noted that...an unwarranted easing in financial conditions, especially if driven by a misperception by the public of the Committee's reaction function, would complicate the Committee's effort to restore price stability." Analysts believe those factors will see push-back from Powell in his press conference. And analysts do not expect him to follow the BoC which slowed its rate hikes to 25 bps and announced a pause. However, risks of a sharp downturn in Q1 growth could see the Fed take its foot off the brakes at the March meeting. Implied Fed funds futures are selling off slightly as the more hawkish tone is priced in. The projected terminal rate has edged up to 4.921% in June, though is still not showing the Fed's 5.1% median dot in 2023.

2023-01-30 09:05:02

$ECON

Economic Data

/ +

09:05

01/30/23

01/30

09:05

01/30/23

09:05

The FOMC meets for the first time in 2023 on Tuesday, Wednesday

The FOMC meets for the first time in 2023 on Tuesday, Wednesday. The policy decision will be announced on Wednesday at 14:00 ET. A stepped down 25 bp hike to a 4.625% rate is widely expected after downshifting to 50 bps in December following four straight 75 bp boosts. Comments from Governor Waller, one of the most hawkish on the Committee, who added his support for a further tapering to 25 bps largely sealed the deal. But, many believe a 50 bps is warranted. Recent data reflect still tight claims numbers and elevated inflation. Also policymakers' desire to achieve the terminal rate as quickly as possible argue for a 50 bps increase. Additionally, the financial markets have continued to ease, something Powell was concerned about and which showed up in the December minutes: "participants noted that...an unwarranted easing in financial conditions, especially if driven by a misperception by the public of the Committee's reaction function, would complicate the Committee's effort to restore price stability." Analysts believe those factors will see push-back from Powell in his press conference. And analysts do not expect him to follow the BoC which slowed its rate hikes to 25 bps and announced a pause. However, risks of a sharp downturn in Q1 growth could see the Fed take its foot off the brakes at the March meeting. Implied Fed funds futures are selling off slightly as the more hawkish tone is priced in. The projected terminal rate has edged up to 4.921% in June, though is still not showing the Fed's 5.1% median dot in 2023.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	FDIC investigating misconduct in management of SVB Financial, Signature Bank » 13:57 03/27/23 03/27 13:57 03/27/23 13:57 SIVB SVB Financial $105.92 / + (+0.00%) , SBNY Signature Bank $69.97 / + (+0.00%) The FDIC released… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SIVB SBNY SIVB SVB Financial $105.92 / + (+0.00%) 09:07 Today First Citizens 'encouraged' by SVB's strong underwriting 09:06 Today First Citizens: Capital ratios remains robust after SVB pact 04:30 Today First Citizens acquires deposits and loans of Silicon Valley Bank 03/23/23 Stifel Financial announces significant expansion of venture banking business SBNY Signature Bank $69.97 / + (+0.00%) 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/22/23 Stronghold Digital reports no direct exposure to SVB, Signature, Silvergate 03/20/23 WhiteHorse Finance says no exposure to Silicon Valley Bank or Signature Bank 03/20/23 OCC conditionally approves Flagstar to buy, assume deposits of Signature SIVB SBNY SIVB SVB Financial $105.92 / + (+0.00%) 03/24/23 Morgan Stanley nCino price target lowered to $27 from $35 at Morgan Stanley 03/23/23 Raymond James Block short report doesn't include 'bombshell,' says Raymond James 03/22/23 BofA Regional bank distress gives CME Group a new growth opportunity, says BofA 03/20/23 Benchmark Aspen Aerogels upgraded to Buy from Hold at Benchmark SBNY Signature Bank $69.97 / + (+0.00%) 03/24/23 Morgan Stanley nCino price target lowered to $27 from $35 at Morgan Stanley 03/22/23 BofA Regional bank distress gives CME Group a new growth opportunity, says BofA 03/22/23 Raymond James New York Community Bancorp resumed with a Strong Buy at Raymond James 03/20/23 BofA New York Community's Signature deal 'could be a significant positive,' says BofA SIVB SBNY SIVB SVB Financial $105.92 / + (+0.00%) 03/10/23 Compugen considers exposure to SVB Financial as immaterial 01/19/23 SVB Financial reports Q4 EPS $4.62, consensus $5.27 10/20/22 SVB Financial reports Q3 EPS $7.21, consensus $6.95 SBNY Signature Bank $69.97 / + (+0.00%) 01/17/23 Signature Bank reports Q4 EPS $4.65, consensus $4.89 10/18/22 Signature Bank reports Q3 EPS $5.57, consensus $5.41 10/17/22 Notable companies reporting before tomorrow's open 10/17/22 Notable companies reporting before tomorrow's open 10 Mar SIVB SBNY SIVB SVB Financial $105.92 / + (+0.00%) 10:20 Today First Republic interest may have cooled SVB auction, CNBC reports 03/24/23 Citizens Financial working on bid for SVB Private, Reuters reports 03/24/23 JPMorgan managed to gain most customers who fled SVB, NY Post reports. 03/22/23 SVB Financial accuses FDIC of 'improer actions,' Reuters reports SBNY Signature Bank $69.97 / + (+0.00%) 03/26/23 Banking stress puts U.S., Europe on watch for credit crunch, Reuters says 03/21/23 $8T mortgage-debt market to be impacted after SVB collapse, WSJ reports 03/17/23 BofA not interested in acquiring Signature Bank, Reuters reports 03/17/23 FDIC open to sharing losses to smooth sale of SVB, Signature, FT says SIVB SBNY SIVB SVB Financial $105.92 / + (+0.00%) 12:04 Today What You Missed On Wall Street This Morning 08:57 Today Fly Intel: Pre-market Movers 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning SBNY Signature Bank $69.97 / + (+0.00%) 03/20/23 What You Missed On Wall Street On Monday 03/20/23 What You Missed On Wall Street This Morning 03/17/23 Here's What You Missed in Crypto This Week 03/15/23 What You Missed On Wall Street On Wednesday 04/19/23 Signature Bank SIVB SBNY SIVB SVB Financial $105.92 / + (+0.00%) 02/02/23 Early notable gainers among liquid option names on February 2nd 01/20/23 Early notable gainers among liquid option names on January 20th 01/19/23 SVB Capital II options imply 7.1% move in share price post-earnings 12/29/22 Early notable gainers among liquid option names on December 29th SBNY Signature Bank $69.97 / + (+0.00%) 03/20/23 Largest borrow rate increases among liquid names 03/09/23 Signature Bank put volume heavy and directionally bearish 01/18/23 Signature Bank put volume heavy and directionally bearish 01/18/23 Early notable gainers among liquid option names on January 18th
General news	Treasury Action: Treasuries are extending losses » 13:55 03/27/23 03/27 13:55 03/27/23 13:55 $ECON Economic Data / + Treasury Action:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/07/23 Powell tells Congress data from January partly reversed softening trends 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says $ECON Economic Data / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/08/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Options	Sarepta call volume above normal and directionally bullish » 13:45 03/27/23 03/27 13:45 03/27/23 13:45 SRPT Sarepta $131.00 / +0.97 (+0.75%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SRPT Sarepta $131.00 / +0.97 (+0.75%) 03/16/23 Sarepta falls 20% after disclosing FDA AdCom meeting to be held for SRP-9001 03/16/23 Sarepta says advisory committee meeting to be held for SRP-9001 02/17/23 Sarepta announces first patient dosed in SRP-9003-102 study 02/13/23 Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4 SRPT Sarepta $131.00 / +0.97 (+0.75%) 03/22/23 TD Cowen Sarepta price target raised to $175 from $125 at TD Cowen 03/17/23 RBC Capital Sarepta price target lowered to $200 from $226 at RBC Capital 03/17/23 Cantor Fitzgerald Sarepta price target lowered to $165 from $178 at Cantor Fitzgerald 03/17/23 Needham Sarepta price target lowered to $160 from $200 at Needham SRPT Sarepta $131.00 / +0.97 (+0.75%) 02/28/23 Sarepta reports Q4 EPS ($1.24), consensus ($1.35) 01/09/23 Sarepta expects to exceed FY22 guidance for net product revenues 11/02/22 Sarepta reports Q EPS (80c), consensus (1.43) SRPT Sarepta $131.00 / +0.97 (+0.75%) 03/20/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 What You Missed On Wall Street On Friday 03/17/23 What You Missed On Wall Street This Morning 03/16/23 Fly Intel: After-Hours Movers 05/29/23 PDUFA Date for SRP-9001
Conference/Events	Jefferies aerospace/defense analyst to hold analyst/industry conference call » 13:45 03/27/23 03/27 13:45 03/27/23 13:45 Aerospace & Defense… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Ohio AG Yost sues Express Scripts, Prime Therapeutics over drug price fixing » 13:38 03/27/23 03/27 13:38 03/27/23 13:38 CI Cigna $263.41 / +3.14 (+1.21%) , HUM Humana $509.05 / +6.59 (+1.31%) In a lawsuit filed on… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CI HUM CI Cigna $263.41 / +3.14 (+1.21%) 02/28/23 Cigna CEO sells $5.92M in common stock 02/02/23 Managed care stocks pressured after CMS' preliminary Medicare Advantage rates 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices 12/06/22 Walmart to pay $500,000 over workers' compensation prescription procedures HUM Humana $509.05 / +6.59 (+1.31%) 03/26/23 Fly Intel: Top five weekend stock stories 03/22/23 Humana Foundation Board of Directors elects Jones as Chairman 03/08/23 Humana receives FSSA recommendation for healthcare contract 02/23/23 Humana to exit Employer Group Commercial Medical Products business CI HUM CI Cigna $263.41 / +3.14 (+1.21%) 02/23/23 JPMorgan Cigna price target lowered to $370 from $378 at JPMorgan 02/08/23 Deutsche Bank Cigna price target lowered to $348 from $359 at Deutsche Bank 02/08/23 SVB Securities Cigna price target lowered to $309 from $335 at SVB Securities 02/06/23 Loop Capital Cigna price target lowered to $320 from $350 at Loop Capital HUM Humana $509.05 / +6.59 (+1.31%) 02/28/23 Deutsche Bank Humana price target lowered to $562 from $575 at Deutsche Bank 02/23/23 BTIG Evolent Health price target raised to $45 from $40 at BTIG 02/07/23 Truist Humana price target lowered to $560 from $580 at Truist 02/06/23 Cowen Humana price target lowered to $581 from $647 at Cowen CI HUM CI Cigna $263.41 / +3.14 (+1.21%) 02/03/23 Cigna sees FY23 adjusted EPS $24.60, consensus $24.84 02/03/23 Cigna reports Q4 adjusted EPS $4.96, consensus $4.86 02/02/23 Notable companies reporting before tomorrow's open 02/02/23 Notable companies reporting before tomorrow's open HUM Humana $509.05 / +6.59 (+1.31%) 03/02/23 Humana and Aledade announce 10 year collaboration 02/01/23 Humana sees FY23 adjusted EPS 'at least' $28.00, consensus $28.00 02/01/23 Humana reports Q4 adjusted EPS $1.62, consensus $1.46 01/31/23 Notable companies reporting before tomorrow's open CI HUM CI Cigna $263.41 / +3.14 (+1.21%) 11:32 Today Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports 01/27/23 Cigna sues CVS Health, Amy Bricker for violating noncompete, Bloomberg Law says 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says 11/07/22 Walgreens-backed VillageMD close to $9B deal with Summit, WSJ reports HUM Humana $509.05 / +6.59 (+1.31%) 11:32 Today Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports 03/26/23 Humana stock a bet on healthcare for seniors, Barron's says 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says 11/29/22 Humana to shut down Jupiter, FL, facility, cut 150+ jobs, SFBJ reports CI HUM CI Cigna $263.41 / +3.14 (+1.21%) 02/03/23 What You Missed On Wall Street On Friday 02/03/23 What You Missed On Wall Street This Morning 02/03/23 Fly Intel: Pre-market Movers 01/27/23 What You Missed On Wall Street This Morning HUM Humana $509.05 / +6.59 (+1.31%) 12/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/26/22 What You Missed On Wall Street This Morning 10/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/26/23 Humana - HUM 05/05/23 Cigna - CI 03/28/23 Cigna 03/29/23 Cigna 04/20/23 Humana Inc. 04/26/23 Cigna Group (The) CI HUM CI Cigna $263.41 / +3.14 (+1.21%) 01/13/23 Early notable gainers among liquid option names on January 13th HUM Humana $509.05 / +6.59 (+1.31%) 01/30/23 Early notable gainers among liquid option names on January 30th 01/19/23 Early notable gainers among liquid option names on January 19th 01/09/23 Humana put volume heavy and directionally bearish 12/16/22 Humana put volume heavy and directionally bearish
Downgrade	Momentive downgraded to Hold from Buy at Truist » 13:33 03/27/23 03/27 13:33 03/27/23 13:33 MNTV Momentive $9.29 / +0.02 (+0.22%) Truist analyst Youssef… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options MNTV Momentive $9.29 / +0.02 (+0.22%) 03/13/23 Momentive Global trading resumes 03/13/23 Momentive to be acquired by Symphony Technology Group for $1.5B in cash 03/13/23 Momentive Global trading halted, news pending 02/16/23 Momentive announces workforce reduction of 14% MNTV Momentive $9.29 / +0.02 (+0.22%) 03/14/23 Wells Fargo Momentive downgraded to Equal Weight from Overweight at Wells Fargo 03/14/23 Craig-Hallum Momentive downgraded to Hold from Buy at Craig-Hallum 03/14/23 Needham Momentive downgraded to Hold from Buy at Needham 08/22/22 Wells Fargo Momentive price target lowered to $15 from $20 at Wells Fargo MNTV Momentive $9.29 / +0.02 (+0.22%) 02/16/23 Momentive sees Q1 revenue flat to up 2%, consensus $124.2M 02/16/23 Momentive reports Q4 adjusted EPS 14c, consensus 10c 11/03/22 Momentive sees Q4 revenue $120M-$122M, consensus $124.2M 11/03/22 Momentive reports Q3 EPS 4c, consensus 4c MNTV Momentive $9.29 / +0.02 (+0.22%) 03/14/23 What You Missed On Wall Street On Tuesday 03/14/23 What You Missed On Wall Street This Morning 03/14/23 Fly Intel: Pre-market Movers MNTV Momentive $9.29 / +0.02 (+0.22%) 03/14/23 Unusually active option classes on open March 14th 01/03/23 Momentive Global call volume above normal and directionally bullish 11/03/22 Momentive Global options imply 9.8% move in share price post-earnings 10/24/22 Momentive Global put volume heavy and directionally bearish
General news	Treasury's $42 B 2-year note auction was very poor » 13:25 03/27/23 03/27 13:25 03/27/23 13:25 $ECON Economic Data / + Treasury's $42 B… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/07/23 Powell tells Congress data from January partly reversed softening trends 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says $ECON Economic Data / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/08/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Conference/Events	Oppenheimer emerging biotech analyst to hold analyst/industry conference call » 13:25 03/27/23 03/27 13:25 03/27/23 13:25 RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) , ARVN Arvinas $26.77 / +0.37 (+1.40%) , OLMA Olema Oncology $3.64 / +0.1 (+2.82%) , AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) , GILD Gilead $80.14 / +0.12 (+0.15%) , AZN AstraZeneca $68.93 / +1.01 (+1.49%) , LLY Eli Lilly $334.19 / -1.865 (-0.55%) Biotechnology Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ARVN OLMA AMAM GILD AZN LLY ARVN Arvinas $26.77 / +0.37 (+1.40%) 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors 11/22/22 Arvinas says ARV-471 achieves clinical benefit rate of 38% in evaluable patients 11/08/22 Arvinas expects cash to fund operations multiple years beyond 2024 OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 12/07/22 Olema announces results from Phase 1b dose escalation study of OP-125 10/26/22 Olema Oncology announces preliminary results from OP-1250 trial AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) 03/07/23 Ambrx Biopharma falls -26.7% 03/07/23 Ambrx Biopharma falls -13.4% 03/07/23 Ambrx Biopharma falls -10.9% 03/06/23 Ambrx Biopharma trading resumes GILD Gilead $80.14 / +0.12 (+0.15%) 03/23/23 Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements 03/21/23 Kite announces primary OS analysis results of Phase 3 ZUMA-7 study 03/20/23 Gilead exercises option to license Nurix's NX-0479 03/20/23 Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics AZN AstraZeneca $68.93 / +1.01 (+1.49%) 05:18 Today Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints 03/23/23 AstraZeneca says Calquence conditionally approved in China for first indication 03/09/23 AstraZeneca announces ADAURA trial meets secondary endpoint 03/09/23 AstraZeneca announces AEGEAN trial demonstrated statistical significance LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/22/23 Roche to collaborate with Lilly on early diagnosis of Alzheimer's disease 03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older RLAY ARVN OLMA AMAM GILD AZN LLY RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) 03/09/23 Guggenheim Relay Therapeutics price target lowered to $28 from $45 at Guggenheim 03/07/23 H.C. Wainwright Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright 02/02/23 Oppenheimer Relay Therapeutics initiated with an Outperform at Oppenheimer 01/19/23 JMP Securities Relay Therapeutics price target lowered to $28 from $38 at JMP Securities ARVN Arvinas $26.77 / +0.37 (+1.40%) 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist 01/12/23 Capital One Arvinas pullback a buying opportunity, says Capital One OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 03/10/23 H.C. Wainwright Olema Oncology price target raised to $15 from $12 at H.C. Wainwright 02/22/23 Credit Suisse Olema Oncology initiated with an Outperform at Credit Suisse 07/06/22 Canaccord Olema Oncology assumed with a Buy at Canaccord 06/09/22 H.C. Wainwright H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) 03/03/23 Baird Ambrx Biopharma price target raised to $11 from $4 at Baird 10/19/22 Baird Ambrx Biopharma price target lowered to $4 from $8 at Baird 09/21/22 Baird Ambrx Biopharma price target lowered to $8 from $16 at Baird 04/07/22 Baird Baird starts Ambrx Biopharma with Outperform, $16 price target GILD Gilead $80.14 / +0.12 (+0.15%) 03/20/23 Oppenheimer Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news 03/13/23 Stifel Arcellx initiated with a Buy at Stifel 02/14/23 Mizuho Gilead price target raised to $101 from $88 at Mizuho 02/10/23 Cowen Gilead price target raised to $95 from $90 at Cowen AZN AstraZeneca $68.93 / +1.01 (+1.49%) 03/15/23 Berenberg AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg 03/07/23 Guggenheim Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs 03/07/23 Evercore ISI Mineralys Therapeutics initiated with an Outperform at Evercore ISI 02/21/23 UBS AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/22/23 Stifel Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data 03/17/23 Stifel Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class' 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo RLAY ARVN OLMA GILD AZN LLY RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) 11/03/22 Relay Therapeutics reports Q3 EPS (76c), consensus (71c) ARVN Arvinas $26.77 / +0.37 (+1.40%) 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) 11/08/22 Arvinas reports Q3 EPS ($1.24), consensus ($1.13) OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 03/09/23 Olema Oncology reports Q4 EPS (65c), consensus (65c) GILD Gilead $80.14 / +0.12 (+0.15%) 02/02/23 Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73 02/02/23 Gilead reports Q4 adjusted EPS $1.67, consensus $1.49 02/02/23 Notable companies reporting after market close 12/20/22 Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c AZN AstraZeneca $68.93 / +1.01 (+1.49%) 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 11/10/22 AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage 11/10/22 AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28 LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 13 Sep AZN LLY AZN AstraZeneca $68.93 / +1.01 (+1.49%) 12/09/22 AstraZeneca says Dato-DXd 'continued to demonstrate encouraging responses' 11/10/22 AstraZeneca drops plans to submit COVID-19 vaccine to U.S. FDA, WSJ reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports RLAY ARVN OLMA GILD AZN LLY RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) 09/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ARVN Arvinas $26.77 / +0.37 (+1.40%) 10/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations GILD Gilead $80.14 / +0.12 (+0.15%) 02/02/23 Fly Intel: After-Hours Movers 12/30/22 What You Missed On Wall Street This Morning 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 What You Missed On Wall Street On Wednesday AZN AstraZeneca $68.93 / +1.01 (+1.49%) 02/09/23 What You Missed On Wall Street This Morning 01/19/23 Biotech Alert: Searches spiking for these stocks today 01/09/23 What You Missed On Wall Street On Monday 01/09/23 What You Missed On Wall Street This Morning LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 14:00 Today Biotechnology 04/03/23 The Future of Oncology Virtual Symposium 04/27/23 Eli Lilly - LLY 04/28/23 Oncologic Drugs Advisory Committee Virtual Meeting 05/01/23 Eli Lilly & Co. 05/03/23 Gilead Sciences Inc. 05/11/23 Gilead AMAM GILD AZN LLY AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) 03/08/23 Ambrx Biopharma call volume above normal and directionally bullish 01/06/23 Largest borrow rate increases among liquid names 12/19/22 Largest borrow rate increases among liquid names 12/15/22 Largest borrow rate increases among liquid names GILD Gilead $80.14 / +0.12 (+0.15%) 02/03/23 Early notable gainers among liquid option names on February 3rd 02/02/23 Gilead options imply 3.5% move in share price post-earnings 11/02/22 Unusually active option classes on open November 2nd 10/28/22 Early notable gainers among liquid option names on October 28th AZN AstraZeneca $68.93 / +1.01 (+1.49%) 11/11/22 AstraZeneca put volume heavy and directionally bearish 11/08/22 AstraZeneca put volume heavy and directionally bearish 10/11/22 AstraZeneca call volume above normal and directionally bullish LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish
Options	Seabridge Gold options imply 2.0% move in share price post-earnings » 13:19 03/27/23 03/27 13:19 03/27/23 13:19 SA Seabridge Gold $12.17 / -0.13 (-1.06%) Pre-earnings options… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Events Options SA Seabridge Gold $12.17 / -0.13 (-1.06%) 11/21/22 B. Riley Seabridge Gold price target raised to $60 from $57 at B. Riley 10/25/22 B. Riley Seabridge Gold price target lowered to $57 from $105 at B. Riley 04/11/23 Seabridge Gold 04/12/23 Seabridge Gold SA Seabridge Gold $12.17 / -0.13 (-1.06%) 03/20/23 Seabridge Gold options imply 2.0% move in share price post-earnings
Hot Stocks	Air Products announces supply contracts from NASA totaling more than $130M » 13:17 03/27/23 03/27 13:17 03/27/23 13:17 APD Air Products $273.80 / +6.04 (+2.26%) Air Products announced it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events APD Air Products $273.80 / +6.04 (+2.26%) 03/23/23 Air Products confirms withdrawal from Indonesia coal gasification projects 01/26/23 Air Products increases quarterly dividend by 8% to $1.75 per share 01/20/23 Air Products' joint venture in Saudi Arabia completes second asset transfer 12/08/22 Air Products, AES Corp. to invest $4B in new Texas green hydrogen facility APD Air Products $273.80 / +6.04 (+2.26%) 03/24/23 BMO Capital Air Products price target lowered to $360 from $386 at BMO Capital 03/13/23 Vertical Research Air Products upgraded to Buy from Hold at Vertical Research 03/07/23 Evercore ISI Evercore adds Air Products to 'Tactical Outperform' list, ups target 02/06/23 Morgan Stanley Air Products price target lowered to $315 from $335 at Morgan Stanley APD Air Products $273.80 / +6.04 (+2.26%) 02/02/23 Air Products backs FY23 adjusted EPS view $11.20-$11.50, consensus $11.39 02/02/23 Air Products sees Q2 adjusted EPS $2.50-$2.70, consensus $2.68 02/02/23 Air Products reports Q1 adjusted EPS $2.64, consensus $2.70 11/03/22 Air Products sees FY23 EPS $11.20-$11.50, consensus $11.37 05/12/23 Annual Growth Discovery Virtual Conference

Technical Analysis	NASDAQ market internals summary » 13:17 03/27/23 03/27 13:17 03/27/23 13:17 $NSD NASDAQ Market Internals / + Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NSD NASDAQ Market Internals / + 12:17 Today NASDAQ market internals summary 11:17 Today NASDAQ market internals summary 10:17 Today NASDAQ market internals summary 03/24/23 NASDAQ market internals summary
Technical Analysis	NYSE market internals summary » 13:16 03/27/23 03/27 13:16 03/27/23 13:16 $NYE NYSE Market Internals / + Volume is average for… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NYE NYSE Market Internals / + 11:16 Today NYSE market internals summary 10:16 Today NYSE market internals summary 03/24/23 NYSE market internals summary 03/24/23 NYSE market internals summary
Earnings	Notable companies reporting before tomorrow's open » 13:13 03/27/23 03/27 13:13 03/27/23 13:13 WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) Notable companies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/14/23 Senate Democrats urge Walmart, Kroger, others to sell mifepristone 03/06/23 Walgreens Boots Alliance to dispense Mifepristone where 'legally permissible' 03/06/23 California 'done' with Walgreens over abortion pill stance 03/02/23 Walgreens with DoorDash, Uber announce free Same Day Rx Delivery for HIV WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/26/23 Barclays Walgreens Boots Alliance price target lowered to $43 from $45 at Barclays 03/22/23 Evercore ISI Walgreens Boots Alliance price target lowered to $35 from $36 at Evercore ISI 02/23/23 Loop Capital Loop Capital starts Walgreens Boots at Buy, sees higher growth from healthcare 02/22/23 Loop Capital Walgreens Boots Alliance initiated with a Buy at Loop Capital WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 01/05/23 Walgreens Boots Alliance backs FY23 adjusted EPS view $4.45-$4.65 01/05/23 Walgreens Boots Alliance reports Q1 adjusted EPS $1.16, consensus $1.13 01/04/23 Notable companies reporting before tomorrow's open 01/04/23 Notable companies reporting before tomorrow's open WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/08/23 Walgreens stops offer abortion pill in 21 states, face blowback, NYTimes report 03/03/23 Walgreens will not distribute abortion pills in 20 states, Reuters report 01/25/23 Walgreens weighing sale of $2B pharmacy automation business, Bloomberg says 01/19/23 Rite Aid plans to provide abortion pill in some stores, Bloomberg reports WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/06/23 What You Missed On Wall Street On Monday 02/25/23 Buy/Sell: Wall Street's top 10 stock calls this week 02/23/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/25/23 What You Missed On Wall Street On Wednesday 03/28/23 Walgreens Boots Alliance - WBA WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 09:40 Today Unusually active option classes on open March 27th 03/13/23 Walgreen Boots call volume above normal and directionally bullish 01/05/23 Unusually active option classes on open January 5th 11/11/22 Unusually active option classes on open November 11th
General news	2-year note auction » 13:09 03/27/23 03/27 13:09 03/27/23 13:09 $ECON Economic Data / + Total Amount: $42B, Rate:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/07/23 Powell tells Congress data from January partly reversed softening trends 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says $ECON Economic Data / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/08/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Hot Stocks	Nano Dimension files lawsuit against Murchinson, Anson and Boothbay » 13:08 03/27/23 03/27 13:08 03/27/23 13:08 NNDM Nano Dimension $2.60 / +0.01 (+0.39%) Nano Dimension has filed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 10:06 Today Nano Dimension announces purchase order from Fraunhofer Institue 03/23/23 Nano Dimension to review options relative to Stratasys and alternative targets 03/23/23 Nano Dimension releases video on products, materials, technologies 03/22/23 Stratasys board unanimously rejects acquisition proposal from Nano Dimension NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/10/23 Lake Street Nano Dimension made 'lowball offer' Stratasys won't accept, says Lake Street NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 01/24/23 Nano Dimension reports Q4 revenue $12.1M, up 61% vs. 4Q21 12/01/22 Nano Dimension reports Q3 EPS (26c) vs. (7c) last year 10/24/22 Nano Dimension sees Q3 revenue $10M NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/07/23 Nano Dimension receives purchase order for DragonFly IV system NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 03/20/23 Fly Intel: After-Hours Movers 03/14/23 What You Missed On Wall Street On Tuesday 03/30/23 Nano Dimension - NNDM NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/07/23 Unusually active option classes on open March 7th 01/20/23 Largest borrow rate increases among liquid names
Upgrade	Novartis upgraded to Hold at Deutsche Bank after Kisqali's 'positive surprise' » 13:07 03/27/23 03/27 13:07 03/27/23 13:07 NVS Novartis $90.14 / +6.555 (+7.84%) Deutsche Bank upgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NVS Novartis $90.14 / +6.555 (+7.84%) 12:00 Today Novartis rises 7.5% 06:46 Today Novartis says Kisqali Phase 3 NATALEE trial met primary endpoint at interim 03/24/23 23andMe pilots program to raise awareness about Lipoprotein(a) 03/21/23 Novartis alpelisib granted FDA orphan designation NVS Novartis $90.14 / +6.555 (+7.84%) 12:59 Today Deutsche Bank Novartis upgraded to Hold from Sell at Deutsche Bank 07:24 Today BofA Novartis' NATALEE readout a 'best case scenario,' says BofA 07:18 Today Morgan Stanley Morgan Stanley expects Novartis to outperform after Kisqali 'positive surprise' 01/26/23 Citi Novartis downgraded to Neutral from Buy at Citi NVS Novartis $90.14 / +6.555 (+7.84%) 02/01/23 Novartis sees core operating income to grow mid single digit percentage in 2023 02/01/23 Novartis reports Q4 core EPS $1.52, consensus $1.44 10/25/22 Novartis confirms mid single digit sales, core operating income guidance 10/25/22 Novartis reports Q3 core EPS $1.58 vs. $1.71 last year NVS Novartis $90.14 / +6.555 (+7.84%) 03/22/23 Novartis halts Leqvio heart attack prevention trial, Reuters reports 02/08/23 Avrobio exploring potential sale after approach, Street Insider says 12/29/22 Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports 11/16/22 Novartis exploring sale of ophthalmology, respiratory units, Bloomberg says NVS Novartis $90.14 / +6.555 (+7.84%) 03/22/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street This Morning 02/10/23 Biotech Alert: Searches spiking for these stocks today 02/01/23 What You Missed On Wall Street This Morning NVS Novartis $90.14 / +6.555 (+7.84%) 01/09/23 Novartis call volume above normal and directionally bullish 12/16/22 Novartis call volume above normal and directionally bullish 10/06/22 Novartis put volume heavy and directionally bearish
Conference/Events	Compass Pathways management to meet virtually with Cantor Fitzgerald » 13:06 03/27/23 03/27 13:06 03/27/23 13:06 CMPS Compass Pathways $10.28 / +0.26 (+2.59%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 02/28/23 Compass Pathways sees 2023 net cash use $85M-$110M 01/26/23 Cathie Wood's ARK Investment bought 120.3K shares of Compass Pathways today 01/19/23 Cathie Wood's ARK Investment bought 158.2K shares of Compass Pathways today 01/18/23 Cathie Wood's ARK Investment bought 156.6K shares of Compass Pathways today CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 01/09/23 Loop Capital Atai Life Sciences price target lowered to $10 from $18 at Loop Capital 12/15/22 EF Hutton Compass Pathways initiated with a Buy at EF Hutton 12/09/22 Oppenheimer Compass Pathways price target lowered to $33 from $55 at Oppenheimer 11/01/22 Loop Capital Compass Pathways initiated with a Buy at Loop Capital CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 02/28/23 Compass Pathways reports Q4 EPS (73c), consensus (59c) 11/03/22 Compass Pathways reports Q3 EPS (43c), consensus (65c) CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 01/03/23 Oregon becomes first U.S. state to legalize 'magic' mushrooms, NYT says CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 03/23/23 Here's What You Missed in Cannabis, Psychedelics This Week 03/16/23 Rising High: Exclusive talk with house of brands Carma HoldCo 03/09/23 Rising High: Exclusive talk with cannabinoid market research firm BDSA 03/02/23 Rising High: Exclusive talk with vertically-integrated MSO Greenlight 03/29/23 Compass Pathways 03/30/23 Compass Pathways
Options	PVH Corp. options imply 5.1% move in share price post-earnings » 13:04 03/27/23 03/27 13:04 03/27/23 13:04 PVH PVH Corp. $73.70 / +0.795 (+1.09%) Pre-earnings options… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PVH PVH Corp. $73.70 / +0.795 (+1.09%) 03/08/23 PVH Corp. names Amber McCann Chief Communications Office 12/01/22 PVH Corp. rises 10.2% 12/01/22 PVH Corp. rises 10.5% 11/30/22 PVH Corp. jumps 9% to $73.38 after Q3 earnings beat, guidance raise PVH PVH Corp. $73.70 / +0.795 (+1.09%) 03/21/23 UBS PVH Corp. price target lowered to $92 from $100 at UBS 03/20/23 Goldman Sachs PVH Corp. price target raised to $74 from $67 at Goldman Sachs 02/15/23 Wells Fargo PVH Corp. price target raised to $110 from $85 at Wells Fargo 01/23/23 JPMorgan PVH Corp. price target raised to $95 from $77 at JPMorgan PVH PVH Corp. $73.70 / +0.795 (+1.09%) 11/30/22 PVH Corp. raises FY22 EPS view to $8.25 from $8, consensus $7.89 11/30/22 PVH Corp. sees Q4 adjusted EPS $1.65, consensus $1.70 11/30/22 PVH Corp. reports Q3 adjusted EPS $2.60, consensus $2.15 11/30/22 Notable companies reporting after market close PVH PVH Corp. $73.70 / +0.795 (+1.09%) 12/01/22 What You Missed On Wall Street On Thursday 12/01/22 What You Missed On Wall Street This Morning 12/01/22 Fly Intel: Pre-market Movers 11/30/22 Fly Intel: After-Hours Movers 03/28/23 PVH Corp. - PVH
Hot Stocks	CN, Trealmont, Kaptan plan for new Calgary intermodal transload facility » 13:02 03/27/23 03/27 13:02 03/27/23 13:02 CNI Canadian National $114.65 / +0.95 (+0.84%) CN, Trealmont Transport… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events CNI Canadian National $114.65 / +0.95 (+0.84%) 03/22/23 North American rail traffic down 6.9% for the week ending March 18 03/20/23 Canadian National, Unifor reach tentative agreements 03/15/23 North American rail traffic down 6.1% for the week ending March 11 03/08/23 North American rail traffic down 4.4% for the week ending March 4 CNI Canadian National $114.65 / +0.95 (+0.84%) 07:12 Today BofA Canadian National price target lowered to $134 from $137 at BofA 01/25/23 Desjardins Canadian National price target lowered to C$179 from C$180 at Desjardins 01/25/23 CIBC Canadian National price target lowered to C$175 from C$181 at CIBC 01/25/23 BMO Capital Canadian National price target lowered to C$180 from C$185 at BMO Capital CNI Canadian National $114.65 / +0.95 (+0.84%) 01/24/23 Canadian National reports Q4 EPS C$2.10, consensus C$2.08 10/25/22 Canadian National raises FY22 adjusted EPS view to up 25% from up 15%-20% 10/25/22 Canadian National reports Q3 adjusted EPS C$2.13 vs. C$2.37 last year CNI Canadian National $114.65 / +0.95 (+0.84%) 03/07/23 Ohio crash highlights gap in federal safety regulations, NY Times reports 03/03/23 Norfolk Southern, railroads to join close-call reporting system, WSJ reports 12/01/22 Senate approves bill to force tentative rail labor agreement, CNBC says 11/30/22 House passes bill to avoid rail strike, NBC News reports CNI Canadian National $114.65 / +0.95 (+0.84%) 01/24/23 Fly Intel: After-Hours Movers 11/30/22 What You Missed On Wall Street On Wednesday 11/29/22 What You Missed On Wall Street On Tuesday 11/29/22 What You Missed On Wall Street This Morning 04/24/23 Canadian National - CNI
Upgrade	Novartis upgraded to Hold from Sell at Deutsche Bank » 12:59 03/27/23 03/27 12:59 03/27/23 12:59 NVS Novartis $90.21 / +6.625 (+7.93%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NVS Novartis $90.21 / +6.625 (+7.93%) 12:00 Today Novartis rises 7.5% 06:46 Today Novartis says Kisqali Phase 3 NATALEE trial met primary endpoint at interim 03/24/23 23andMe pilots program to raise awareness about Lipoprotein(a) 03/21/23 Novartis alpelisib granted FDA orphan designation NVS Novartis $90.21 / +6.625 (+7.93%) 07:24 Today BofA Novartis' NATALEE readout a 'best case scenario,' says BofA 07:18 Today Morgan Stanley Morgan Stanley expects Novartis to outperform after Kisqali 'positive surprise' 01/26/23 Citi Novartis downgraded to Neutral from Buy at Citi 01/24/23 Lake Street Harrow Health price target raised to $24 from $17 at Lake Street NVS Novartis $90.21 / +6.625 (+7.93%) 02/01/23 Novartis sees core operating income to grow mid single digit percentage in 2023 02/01/23 Novartis reports Q4 core EPS $1.52, consensus $1.44 10/25/22 Novartis confirms mid single digit sales, core operating income guidance 10/25/22 Novartis reports Q3 core EPS $1.58 vs. $1.71 last year NVS Novartis $90.21 / +6.625 (+7.93%) 03/22/23 Novartis halts Leqvio heart attack prevention trial, Reuters reports 02/08/23 Avrobio exploring potential sale after approach, Street Insider says 12/29/22 Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports 11/16/22 Novartis exploring sale of ophthalmology, respiratory units, Bloomberg says NVS Novartis $90.21 / +6.625 (+7.93%) 03/22/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street This Morning 02/10/23 Biotech Alert: Searches spiking for these stocks today 02/01/23 What You Missed On Wall Street This Morning NVS Novartis $90.21 / +6.625 (+7.93%) 01/09/23 Novartis call volume above normal and directionally bullish 12/16/22 Novartis call volume above normal and directionally bullish 10/06/22 Novartis put volume heavy and directionally bearish

Hot Stocks	BioMarin granted orphan status for DMD treatment » 12:58 03/27/23 03/27 12:58 03/27/23 12:58 BMRN BioMarin $91.67 / +0.985 (+1.09%) The FDA granted BioMarin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BMRN BioMarin $91.67 / +0.985 (+1.09%) 03/07/23 BioMarin: FDA accepts sNDA to expand use of VOXZOGO for injection 03/06/23 BioMarin says FDA extends review of BLA for Roctavian 01/08/23 BioMarin announces data from follow up from Phase 3 GENEr8-1 study of ROCTAVIAN 01/03/23 BioMarin's application for Voxzogo in achondroplasia validated by EMA BMRN BioMarin $91.67 / +0.985 (+1.09%) 03/21/23 Bernstein BioMarin initiated with an Underperform at Bernstein 03/09/23 Chardan Tenaya Therapeutics price target lowered to $24 from $28 at Chardan 02/28/23 Stifel BioMarin price target raised to $118 from $114 at Stifel 02/28/23 Wedbush BioMarin price target lowered to $74 from $83 at Wedbush BMRN BioMarin $91.67 / +0.985 (+1.09%) 02/27/23 BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61 02/27/23 BioMarin reports Q4 EPS (0c), consensus (7c) 02/27/23 Notable companies reporting after market close 10/26/22 BioMarin backs FY22 revenue view $2.06B-$2.16B, consensus $2.12B BMRN BioMarin $91.67 / +0.985 (+1.09%) 03/24/23 Buy/Sell: Wall Street's top 10 stock calls this week 03/21/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/21/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/30/23 PDUFA Date for Roctavian--Extended 10/21/23 PDUFA Date for VOXZOGO
Hot Stocks	Incyte granted orphan status for myelofibrosis treatment » 12:57 03/27/23 03/27 12:57 03/27/23 12:57 INCY Incyte $70.82 / +0.59 (+0.84%) The FDA granted Incyte… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options INCY Incyte $70.82 / +0.59 (+0.84%) 05:20 Today Incyte announces Japanese MHLW approval of Pemazyre 03/23/23 Incyte provides regulatory update on Ruxolitinib extended relief 03/22/23 MacroGenics to receive $15M milestone following FDA approval of Zynyz 03/22/23 Incyte announces FDA accelerated approval of Zynyz INCY Incyte $70.82 / +0.59 (+0.84%) 03/24/23 SVB Securities Incyte upgraded to Market Perform at SVB after ruxolitinib XR CRL, Zynz approval 03/24/23 SVB Securities Incyte upgraded to Market Perform from Underperform at SVB Securities 03/24/23 BofA BofA sees minimal near-term impact on Incyte from ruxolitinib ER CRL 02/08/23 Cowen Incyte price target raised to $100 from $95 at Cowen INCY Incyte $70.82 / +0.59 (+0.84%) 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open 02/06/23 Notable companies reporting before tomorrow's open 11/01/22 Incyte reports Q3 EPS 60c, consensus 72c INCY Incyte $70.82 / +0.59 (+0.84%) 01/31/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/10/23 Incyte 04/11/23 Incyte INCY Incyte $70.82 / +0.59 (+0.84%) 11/01/22 Early notable gainers among liquid option names on November 1st
Hot Stocks	Centene appoints Tanya McNally as Chief People Officer » 12:49 03/27/23 03/27 12:49 03/27/23 12:49 CNC Centene $64.58 / +0.545 (+0.85%) Centene announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CNC Centene $64.58 / +0.545 (+0.85%) 02/08/23 California AG announces $215M settlement against Centene 02/02/23 Managed care stocks pressured after CMS' preliminary Medicare Advantage rates 01/23/23 Centene completes divestiture of Magellan Specialty Health to Evolent Health 01/03/23 Centene's Health Net selected for new medi-cal direct contracts CNC Centene $64.58 / +0.545 (+0.85%) 03/21/23 Wells Fargo Molina Healthcare price target lowered to $282 from $307 at Wells Fargo 03/21/23 Wells Fargo Centene price target lowered to $71 from $79 at Wells Fargo 03/08/23 Deutsche Bank Centene downgraded to Hold on estimate risk at Deutsche Bank 03/08/23 Deutsche Bank Centene downgraded to Hold from Buy at Deutsche Bank CNC Centene $64.58 / +0.545 (+0.85%) 02/07/23 Centene backs FY23 adjusted EPS view $6.25-$6.40, consensus $6.36 02/07/23 Centene reports Q4 EPS 86c, consensus 85c 02/06/23 Notable companies reporting before tomorrow's open 02/06/23 Notable companies reporting before tomorrow's open CNC Centene $64.58 / +0.545 (+0.85%) 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says CNC Centene $64.58 / +0.545 (+0.85%) 03/08/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/23/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/03/23 What You Missed On Wall Street On Tuesday 01/03/23 What You Missed On Wall Street This Morning 04/25/23 Centene - CNC 05/10/23 Centene Corp. CNC Centene $64.58 / +0.545 (+0.85%) 01/17/23 Centene call volume above normal and directionally bullish 01/09/23 Centene put volume heavy and directionally bearish 12/22/22 Early notable gainers among liquid option names on December 22nd 11/21/22 Centene put volume heavy and directionally bearish
Hot Stocks	Kludein I Acquisition Corp trading resumes 12:43 03/27/23 03/27 12:43 03/27/23 12:43 NIR Near Intelligence $6.20 / -6.15 (-49.80%) ShowHide Related Items >><< Company News NIR Near Intelligence $6.20 / -6.15 (-49.80%) 12:38 Today Kludein I Acquisition Corp trading halted, volatility trading pause 03/23/23 Near Intelligence completes business combination, to trade on Nasdaq
Conference/Events	Payoneer Global management to meet with Cantor Fitzgerald » 12:40 03/27/23 03/27 12:40 03/27/23 12:40 PAYO Payoneer Global $6.06 / +0.015 (+0.25%) Group luncheon meeting… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 03/10/23 Payoneer says less than $20M of cash balances held at SVB 02/28/23 Payoneer Global appoints John Caplan as CEO, effective March 1 02/17/23 Payoneer Global receives UK E-Money license from Financial Conduct Authority 01/18/23 Payoneer appoints Ordonez as deputy CFO PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 02/27/23 Jefferies Payoneer Global initiated with a Buy at Jefferies 01/11/23 Wolfe Research Payoneer Global initiated with an Outperform at Wolfe Research 12/30/22 Northland Payoneer Global named a top pick for 2023 at Northland 11/10/22 Citi Payoneer Global price target raised to $10 from $9 at Citi PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 02/28/23 Payoneer Global sees FY23 revenue $800M-$810M, consensus $738.4M 02/28/23 Payoneer Global reports Q4 EPS (3c), consensus (5c) 11/09/22 Payoneer Global sees FY22 revenue $605M-$615M, consensus $598.11M 11/09/22 Payoneer Global reports Q3 EPS (8c), consensus (2c) PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 02/28/23 Fly Intel: After-Hours Movers 10/10/22 What You Missed On Wall Street On Monday 10/10/22 What You Missed On Wall Street This Morning 10/07/22 What You Missed On Wall Street On Friday 03/29/23 Payoneer Global PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 11/16/22 Payoneer Global call volume above normal and directionally bullish